---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-158979"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:10:25.042138+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Catalyst reaffirms FY2023 revenue $375M-$385M; non-GAAP net income $195M-$205M

## Summary
- Reaffirms full-year 2023 total revenue guidance of $375M to $385M, 75-80% YoY increase.
- FIRDAPSE net product revenue guided $245M-$255M, up 17% vs. 2022.
- FYCOMPA net product revenue forecast at ~$130M for 11 months after Jan. 24 acquisition.
- Non-GAAP net income forecast of $195M to $205M for full-year 2023.

## SEC filing metadata
- accession: 0001193125-23-158979
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523158979/0001193125-23-158979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523158979/d463989d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-158979
- JSON: https://secwatch.observer/filing/0001193125-23-158979.json
- Plain text: https://secwatch.observer/filing/0001193125-23-158979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.